Company Also Enters Into Accelerated Share Repurchase Agreement
NEW YORK, Dec. 7, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced today that its Board of Directors recently authorized a new share repurchase program to acquire up to an additional $1 billion of the company's outstanding common shares.
Separately, the company also announced that in November it entered into an accelerated share repurchase agreement to acquire $150 million of Edwards' common stock. Upon entering into the agreement, Edwards received and retired an initial delivery of 1.1 million shares. In addition, earlier in the fourth quarter, Edwards repurchased approximately $100 million of common stock.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.
View original content with multimedia:http://www.prnewswire.com/news-releases/edwards-lifesciences-board-approves-new-1-billion-share-repurchase-program-300568177.html